[go: up one dir, main page]

MX9305764A - Procedimiento para la preparacion de los esteres de la bacatina iii y dela 10-desacetil bacatina iii y productos obtenidos por medio del mismo. - Google Patents

Procedimiento para la preparacion de los esteres de la bacatina iii y dela 10-desacetil bacatina iii y productos obtenidos por medio del mismo.

Info

Publication number
MX9305764A
MX9305764A MX9305764A MX9305764A MX9305764A MX 9305764 A MX9305764 A MX 9305764A MX 9305764 A MX9305764 A MX 9305764A MX 9305764 A MX9305764 A MX 9305764A MX 9305764 A MX9305764 A MX 9305764A
Authority
MX
Mexico
Prior art keywords
bacatin iii
esters
preparation
desacetile
dela
Prior art date
Application number
MX9305764A
Other languages
English (en)
Inventor
Jean-Noel Denis
Andrew Greene
Jean-Manual Mas
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of MX9305764A publication Critical patent/MX9305764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención concierne a la preparación de ésteres de la bacatinaIII y de la 10-desacetil bacatina III, de fórmula general: medianteesterificación de la bacatina III o de la 10-desacetil bacatina IIIprotegida convenientemente, de fórmula general: por medio de un ácidoactivado de fórmula general:.
MX9305764A 1992-10-05 1993-09-21 Procedimiento para la preparacion de los esteres de la bacatina iii y dela 10-desacetil bacatina iii y productos obtenidos por medio del mismo. MX9305764A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9211739A FR2696464B1 (fr) 1992-10-05 1992-10-05 Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.

Publications (1)

Publication Number Publication Date
MX9305764A true MX9305764A (es) 1995-01-31

Family

ID=9434116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305764A MX9305764A (es) 1992-10-05 1993-09-21 Procedimiento para la preparacion de los esteres de la bacatina iii y dela 10-desacetil bacatina iii y productos obtenidos por medio del mismo.

Country Status (24)

Country Link
US (2) US5717103A (es)
EP (1) EP0663905B1 (es)
JP (1) JP3064419B2 (es)
KR (1) KR100290663B1 (es)
AT (1) ATE147734T1 (es)
AU (1) AU689446B2 (es)
CA (1) CA2146372C (es)
CZ (1) CZ284818B6 (es)
DE (1) DE69307526T2 (es)
DK (1) DK0663905T3 (es)
ES (1) ES2096328T3 (es)
FI (1) FI115909B (es)
FR (1) FR2696464B1 (es)
GR (1) GR3022286T3 (es)
HU (1) HU225973B1 (es)
MX (1) MX9305764A (es)
NO (1) NO313141B1 (es)
NZ (1) NZ256443A (es)
PL (1) PL178090B1 (es)
RU (1) RU2123493C1 (es)
SK (1) SK281035B6 (es)
TW (1) TW372234B (es)
WO (1) WO1994007876A1 (es)
ZA (1) ZA937316B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2698361B1 (fr) * 1992-11-20 1995-01-13 Rhone Poulenc Rorer Sa Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
MX9307777A (es) 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
SI0703909T1 (en) * 1993-06-11 2000-08-31 Pharmacia & Upjohn Company Delta 6,7 -taxols antineoplastic use and pharmaceutical compositions containing them
KR20090090403A (ko) 1993-07-19 2009-08-25 더 유니버시티 오브 브리티쉬 콜롬비아 항맥관형성 조성물, 당해 조성물로 피복된 스텐트 및 당해 스텐트의 제조방법
CA2172809A1 (en) * 1993-11-12 1995-05-18 Richard A. Nugent Pyrimidine-thioalkyl and alkylether compounds
IL127597A (en) * 1994-01-28 2003-07-31 Upjohn Co Iso-taxol analogs
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
CN1216039A (zh) * 1996-05-08 1999-05-05 法玛西雅厄普约翰美国公司 制备紫杉酚的方法
US6150537A (en) * 1997-12-12 2000-11-21 Emory University Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents
JP4502338B2 (ja) * 1999-09-17 2010-07-14 株式会社横浜国際バイオ研究所 タキソイド化合物の製造法
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
MXPA03002494A (es) 2000-09-22 2004-05-24 Bristol Myers Squibb Co Metodo para reducir toxicidad de quimio terapias combinadas.
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
CA2440935A1 (en) 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
PT1392254E (pt) * 2001-04-20 2007-06-29 Univ British Columbia Sistemas de distribuição micelares de fármacos para fármacos hidrofóbicos.
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ITMI20021921A1 (it) * 2002-09-10 2004-03-11 Indena Spa Funzionalizzazione della posizione 14 dei nuclei tassanici e sintesi di nuovi derivati antitumorali.
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006089218A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating angiogenesis
CA2646156C (en) 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
EP2859916B1 (en) 2008-05-22 2017-11-29 Galera Labs, LLC Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy
CA2724130C (en) 2008-06-06 2016-04-26 Harbor Biosciences, Inc. Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP2874650A4 (en) 2012-07-19 2016-03-23 Redwood Bioscience Inc FOR CD22 SPECIFIC ANTIBODIES AND METHOD FOR USE THEREOF
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
KR102132246B1 (ko) 2013-02-15 2020-07-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
AU2014354643B2 (en) 2013-11-27 2020-03-05 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
WO2015127137A1 (en) 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
JP6083815B2 (ja) * 2014-03-07 2017-02-22 立川ブラインド工業株式会社 タッセル
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF
IL312621A (en) 2016-06-01 2024-07-01 Servier Ip Uk Ltd Compositions of polyalkylene oxide-asparaginase and methods for their preparation and use
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
CN110177808A (zh) 2017-01-18 2019-08-27 F1肿瘤医学公司 针对axl或ror2的嵌合抗原受体及其使用方法
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3630189A4 (en) 2017-05-24 2021-06-23 The Board of Regents of The University of Texas System LINKER FOR ANTIBODY MEDICINAL CONJUGATES
JP2021512110A (ja) 2018-01-31 2021-05-13 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
WO2019195596A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California Methods of treating egfrviii expressing glioblastomas
JP2021521173A (ja) 2018-04-11 2021-08-26 オハイオ・ステイト・イノベーション・ファウンデーション 眼内薬物送達用の持続放出微粒子のための方法及び組成物
EP3823674A4 (en) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF
WO2020148612A1 (en) 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CN113692413A (zh) 2019-04-02 2021-11-23 肯乔克蒂生物技术股份有限公司 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法
BR112022011158A2 (pt) 2019-12-12 2022-08-30 Ignite Immunotherapy Inc Vírus vaccinia oncolítico variante e métodos de uso do mesmo
MX2022009355A (es) 2020-01-29 2022-09-02 Kenjockety Biotechnology Inc Anticuerpo anti-mdr1 y uso del mismo.
US20230212305A1 (en) 2020-06-04 2023-07-06 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
JP7768902B2 (ja) 2020-06-04 2025-11-12 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 Ａｂｃｇ２排出ポンプ－がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法
AU2021310520A1 (en) 2020-07-14 2023-02-16 Pfizer Inc. Recombinant vaccinia virus
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
AU2021380659A1 (en) 2020-11-13 2023-06-01 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
AU2021382033A1 (en) 2020-11-20 2023-06-22 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
EP4448007A1 (en) 2021-12-13 2024-10-23 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34277A (en) * 1862-01-28 Improvement in lamps
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
USRE34277E (en) * 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696460B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.

Also Published As

Publication number Publication date
RU95110766A (ru) 1996-12-27
FI951593L (fi) 1995-04-04
HU225973B1 (en) 2008-02-28
JP3064419B2 (ja) 2000-07-12
FI115909B (fi) 2005-08-15
CA2146372C (fr) 2003-09-09
NO951200D0 (no) 1995-03-29
KR100290663B1 (ko) 2001-09-17
FR2696464A1 (fr) 1994-04-08
ES2096328T3 (es) 1997-03-01
HUT72616A (en) 1996-05-28
KR950703545A (ko) 1995-09-20
PL178090B1 (pl) 2000-02-29
DE69307526D1 (de) 1997-02-27
AU5114893A (en) 1994-04-26
ZA937316B (en) 1994-04-22
US5977375A (en) 1999-11-02
HU9500970D0 (en) 1995-06-28
PL308239A1 (en) 1995-07-24
NO951200L (no) 1995-03-29
FR2696464B1 (fr) 1994-11-10
AU689446B2 (en) 1998-04-02
GR3022286T3 (en) 1997-04-30
ATE147734T1 (de) 1997-02-15
JPH08501787A (ja) 1996-02-27
CZ284818B6 (cs) 1999-03-17
WO1994007876A1 (fr) 1994-04-14
TW372234B (en) 1999-10-21
NZ256443A (en) 1996-07-26
RU2123493C1 (ru) 1998-12-20
NO313141B1 (no) 2002-08-19
SK43895A3 (en) 1995-08-09
CZ83995A3 (en) 1995-09-13
FI951593A0 (fi) 1995-04-04
DE69307526T2 (de) 1997-05-22
EP0663905A1 (fr) 1995-07-26
DK0663905T3 (da) 1997-02-03
SK281035B6 (sk) 2000-11-07
CA2146372A1 (fr) 1994-04-14
EP0663905B1 (fr) 1997-01-15
US5717103A (en) 1998-02-10

Similar Documents

Publication Publication Date Title
MX9305764A (es) Procedimiento para la preparacion de los esteres de la bacatina iii y dela 10-desacetil bacatina iii y productos obtenidos por medio del mismo.
MX9305767A (es) Procedimiento para la preparacion de derivados de taxano y los derivados de taxano asi obtenidos.
MX9305766A (es) Procedimiento para la preparacion de derivados de taxano y productosobtenidos por medio del mismo.
ES2179823T3 (es) Inmunosupresor macrolido.
ES2116436T3 (es) Carbamatos y agentes protectores de las plantas que les contienen.
DK0639577T3 (da) Phosphonooxymethyl- eller methylthiomethylestere af taxanderivater som antitumormidler
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
MX9305769A (es) Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2196054T3 (es) Derivados de acido fenilacetico, procedimiento y productos intermedios para su obtencion y agentes que contienen los mismos.
CY1109343T1 (el) Παραγωγα αζετιδινης, η παρασκευη τους και οι φαρμακευτικες ενωσεις που τα περιεχουν
FI924311A0 (fi) Nya 2-substituerade indan-2 -merkaptoacetylamidderivat anvaendbara som inhibitorer av enkefalinas och ace.
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
ES2140456T3 (es) Derivado de diester fosfonico.
ES2170147T3 (es) Metodo para mejorar la eficacia de los productos quimicos agricolas.
ES2045180T3 (es) Nuevo procedimiento para la obtencion de 4-aciloxi-3-hidroxietil-azetidinonas.
MX9204865A (es) Proceso para alcoxilacion de esteres y los productos elaborados.
ES2119300T3 (es) Procedimiento para la preparacion de 5-formilvalerato.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
BR0007643A (pt) Processo para obter ésteres de (nitroximetil) fenila de derivados de aspirina, e, (hidroximetil) feniléter de derivados de aspirina
ES2133418T3 (es) Procedimiento para la preparacion de derivados del taxano.
MX9201563A (es) Dexilosilbenanomicina b y procedimiento para prepararla.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
MX9301268A (es) Procedimiento para la preparacion de la beta-fenilisoserina y sus analogos y productos obtenidos mediante el mismo.
ES2057262T3 (es) Derivados del cromano.